Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | RA |
Day after second shot she experienced fever; She also experienced arm pain for first 2 days; This non-serious case was reported by a consumer via call center representative and described the occurrence of fever in a 40-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in September 2024). Concurrent medical conditions included systemic lupus erythematosus, asthma and cytomegalovirus infection (Chronic). Concomitant products included hydroxychloroquine, azathioprine and valaciclovir (Valacyclovir). On 06-FEB-2025, the patient received the 2nd dose of Shingrix (right deltoid). On 07-FEB-2025, 1 days after receiving Shingrix, the patient experienced fever (Verbatim: Day after second shot she experienced fever). In FEB-2025, the patient experienced pain in arm (Verbatim: She also experienced arm pain for first 2 days). In FEB-2025, the outcome of the pain in arm was resolved (duration 2 days). The outcome of the fever was not resolved. It was unknown if the reporter considered the fever and pain in arm to be related to Shingrix. It was unknown if the company considered the fever and pain in arm to be related to Shingrix. Additional Information: GSK Receipt Date: 27-FEB-2025 The patient received Shingrix and the day after second shot she experienced fever which was still present. She also experienced arm pain for first 2 days. No other details were provided.
Asthma; Cytomegalovirus infection (Chronic); Systemic lupus erythematosus
HYDROXYCHLOROQUINE; AZATHIOPRINE; VALACYCLOVIR